Previous studies suggested that baseline white blood cell count and apolipoprotein A1 levels were associated with clinical outcomes in patients with coronary heart disease (CAD) who underwent percutaneous coronary intervention (PCI). However, the ratio of baseline white blood cell count-to-apolipoprotein A1 level (WAR) and CAD after PCI have not been investigated. The present study investigated the effects of baseline WAR on long-term outcomes after PCI in patients with CAD. A total of 6050 patients with CAD who underwent PCI were included in the study. Of these, 372 patients were excluded because no baseline white blood cell counts or apolipoprotein A1 (ApoA1) data was available or because of malignancies or other diseases. Finally, 5678 patients were enrolled in the present study and were divided into 3 groups according to WAR value: lower group - WAR< 5.25 (n = 1889); median group - 5.25 ≤ WAR≤7.15 (n = 1892); and higher group - WAR≥7.15 (n = 1897). The primary endpoint was long-term mortality, including all-cause mortality (ACM) and cardiac mortality (CM), after PCI. The average follow-up time was 35.9 ± 22.6 months. A total of 293 patients developed ACM, including 85 (4.5%) patients in the lower group, 90 (4.8%) patients in the median group, and 118 (6.2%) patients in the higher group. The risk of ACM, cardiac mortality (CM), major adverse cardiovascular and cerebrovascular events (MACCEs), and major adverse cardiovascular events (MACEs) increased 62.6% (hazard risk [HR] =1.626, 95%CI: 1.214–2.179, P = 0.001), 45.5% (HR = 1.455, 95%CI: 1.051–2.014, P = 0.024), 21.2% (HR = 1.212, 95%CI: 1.011–1.454, P = 0.038), and 23.8% (HR = 1.238, 95%CI: 1.025–1.495, P = 0.027), respectively, as determined by multivariate Cox regression analyses comparing the patients in the higher group to patients in the lower group. Patients with a WAR≥4.635 had 92.3, 81.3, 58.1 and 58.2% increased risks of ACM, CM, MACCEs and MACEs, respectively, compared to the patients with WAR< 4.635. Every 1 unit increase in WAR was associated with 3.4, 3.2, 2.0 and 2.2% increased risks of ACM, CM, MACCEs and MACEs, respectively, at the 10-year follow-up. The present study indicated that baseline WAR is a novel and an independent predictor of adverse long-term outcomes in CAD patients who underwent PCI.

中文翻译：

---

回顾性队列研究表明，基线白细胞计数与载脂蛋白A1的比率可作为经皮冠状动脉介入治疗患者长期不良预后的新预测指标

先前的研究表明，经皮冠状动脉介入治疗（PCI）的冠心病（CAD）患者的基线白细胞计数和载脂蛋白A1水平与临床结局相关。但是，尚未研究PCI后基线白细胞计数与载脂蛋白A1水平（WAR）和CAD的比率。本研究调查了基线WAR对冠心病患者PCI术后长期结局的影响。研究共纳入6050例行PCI的CAD患者。在这些患者中，有372名患者被排除在外，因为没有基线白细胞计数或载脂蛋白A1（ApoA1）数据可用，或者是由于恶性肿瘤或其他疾病。最后，本研究纳入了5678名患者，并根据WAR值将其分为3组：下组-WAR <5.25（n = 1889）; 中位组-5.25≤WAR≤7.15（n = 1892）; 更高的组-WAR≥7.15（n = 1897）。主要终点是PCI后的长期死亡率，包括全因死亡率（ACM）和心脏死亡率（CM）。平均随访时间为35.9±22.6个月。共有293位患者发生ACM，其中低位组为85（4.5％），中位组为90（4.8％），高位组为118（6.2％）。ACM，心脏死亡率（CM），主要不良心血管和脑血管事件（MACCE）和主要不良心血管事件（MACEs）的风险增加了62.6％（危险风险[HR] = 1.626，95％CI：1.214–2.179，P = 0.001），45.5％（HR = 1.455、95％CI：1.051–2.014，P = 0.024），21.2％（HR = 1.212、95％CI：1.011–1.454，​​P = 0.038）和23.8％（HR = 1.238，95％CI：1.025–1.495，P = 0.027），通过多元Cox回归分析确定，分别比较较高组中的患者和较低组中的患者。与WAR <4.635的患者相比，WAR≥4.635的患者发生ACM，CM，MACCE和MACE的风险分别增加92.3、81.3、58.1和58.2％。在10年的随访中，每增加1单位的WAR分别使ACM，CM，MACCE和MACE的风险增加3.4、3.2、2.0和2.2％。本研究表明，基线WAR是接受PCI的CAD患者长期不良预后的新颖且独立的预测因子。与WAR <4.635的患者相比。在10年的随访中，每增加1单位的WAR分别使ACM，CM，MACCE和MACE的风险增加3.4、3.2、2.0和2.2％。本研究表明，基线WAR是接受PCI的CAD患者长期不良预后的新颖且独立的预测因子。与WAR <4.635的患者相比。在10年的随访中，每增加1单位的WAR分别使ACM，CM，MACCE和MACE的风险增加3.4、3.2、2.0和2.2％。本研究表明，基线WAR是接受PCI的CAD患者长期不良预后的新颖且独立的预测因子。